tasimelteon (VEC-162)

^[1]^[2]

Indications

10, 20, 50, or 100 mg PO QHS

↑ Rajaratnam SMW et al Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: Two randomised controlled multicentre trials. Lancet 2009 Feb 7; 373:482. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19054552
Cardinali DP and Golombek DA. Let there be sleep - On time. Lancet 2009 Feb 7; 373:439. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19054553
↑ ^2.0 ^2.1 FDA News Release: Jan. 31, 2014 FDA approves Hetlioz: first treatment for non-24 hour sleep-wake disorder in blind individuals. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm384092.htm